Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $166,729.08 in Stock

Key Points

• Alphatec Holdings, Inc. EVP Craig E. Hunsaker sold 10,876 shares for a total of $166,729.08, reducing his holding to 1,389,142 shares valued at approximately $21.3 million.
• The company's recent quarterly earnings report showed earnings per share (EPS) of $0.02, exceeding estimates and achieving a 27.5% year-over-year revenue growth.
• Equities analysts have set a consensus target price of $18.50 for Alphatec, with several firms maintaining a "buy" rating on the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig E. Hunsaker sold 10,876 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total transaction of $166,729.08. Following the transaction, the executive vice president owned 1,389,142 shares in the company, valued at $21,295,546.86. This trade represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alphatec Stock Up 2.7%

Shares of Alphatec stock traded up $0.41 during midday trading on Monday, hitting $15.38. The company's stock had a trading volume of 236,346 shares, compared to its average volume of 2,061,828. The firm has a market capitalization of $2.28 billion, a P/E ratio of -13.61 and a beta of 1.05. The stock has a 50-day simple moving average of $11.63 and a 200-day simple moving average of $11.28. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $15.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. Alphatec's revenue was up 27.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.29) earnings per share. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Investors Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Western Wealth Management LLC raised its stake in shares of Alphatec by 5.1% during the 2nd quarter. Western Wealth Management LLC now owns 91,511 shares of the medical technology company's stock worth $1,016,000 after purchasing an additional 4,461 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in Alphatec by 1.1% during the second quarter. Rockefeller Capital Management L.P. now owns 405,254 shares of the medical technology company's stock valued at $4,498,000 after buying an additional 4,528 shares in the last quarter. Intech Investment Management LLC raised its holdings in Alphatec by 43.1% during the second quarter. Intech Investment Management LLC now owns 83,652 shares of the medical technology company's stock valued at $929,000 after buying an additional 25,179 shares in the last quarter. Olympiad Research LP bought a new position in Alphatec during the second quarter valued at about $127,000. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Alphatec by 15.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 26,784 shares of the medical technology company's stock valued at $297,000 after buying an additional 3,634 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Barclays reissued an "overweight" rating and issued a $22.00 price objective (up from $21.00) on shares of Alphatec in a report on Monday, August 4th. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target for the company in a research note on Monday, June 16th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Alphatec has an average rating of "Buy" and an average target price of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.